Patents by Inventor Yun He

Yun He has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240050583
    Abstract: The present application relates to a protein-drug conjugate, containing an antigen binding protein portion and a drug conjugate portion. The antigen binding protein portion comprises one or more antigen binding fragments, and at least two linker peptides are directly or indirectly connected to the antigen binding fragments. The two linker peptides can each independently contain a first cysteine Cys1 and a second cysteine Cys2. The drug conjugate portion is covalently bonded on Cys1. The present application further relates to a preparation method for the protein-drug conjugate, and a use for the protein-drug conjugate in preventing or treating tumors or other diseases.
    Type: Application
    Filed: March 25, 2021
    Publication date: February 15, 2024
    Applicant: HARBOUR BIOMED (SHANGHAI) CO., LTD
    Inventors: Yun HE, Lei SHI, Yang CAO, Ming WANG, Yun ZHANG
  • Publication number: 20230361537
    Abstract: The present disclosure relates to a laser coupling device, which includes a plurality of laser units, configured to emit laser beams; and at least one first convex lens, arranged on optical paths of the laser beams and configured to converge the laser beam. The laser coupling device can emit laser beam with a high power.
    Type: Application
    Filed: August 10, 2022
    Publication date: November 9, 2023
    Inventors: YUN HE, HUIGANG LIN, ZEBIN LI
  • Publication number: 20230362374
    Abstract: An decoding method is disclosed, including: parsing a bitstream to obtain a first flag, wherein the first flag specifies whether a current coding block is required to be partitioned; when the first flag specifies that the current coding block is required to be partitioned, parsing the bitstream to obtain a second flag, wherein the second flag specifies whether the current coding blocks is partitioned in a horizontal direction or a vertical direction; partitioning the current coding block into four first rectangular subblocks in the horizontal direction or four second rectangular subblocks in the vertical direction; and reconstructing the current coding block based on the four first rectangular subblocks or the four second rectangular subblocks.
    Type: Application
    Filed: July 21, 2023
    Publication date: November 9, 2023
    Inventors: Changcai Lai, Xiaoran Cao, Yongbing Lin, Lingzhi Liu, Yun He
  • Publication number: 20230357425
    Abstract: Provided an isolated antigen binding protein having one or more of the following properties: a. capable of binding to both human CD73 and Cynomolgus monkey CD73; b. capable of inhibiting 5?ectonucleotidase activity of CD73; c. capable of mediating CD73 internalization; d. capable of promoting T cell proliferation; e. with a relatively stable concentration in serum; and f. capable of inhibiting tumor growth and/or tumor cell proliferation. In addition, provided a method for producing the isolated antigen binding protein as well as pharmaceutical uses of the isolated antigen binding protein in preventing, alleviating and/or treating tumor.
    Type: Application
    Filed: August 20, 2020
    Publication date: November 9, 2023
    Applicant: Harbour BioMed (Shanghai) Co., Ltd
    Inventors: Lei SHI, Xin GAN, Qianqian SHAN, Yiping RONG, Yun HE
  • Patent number: 11801236
    Abstract: The present invention provides a method for improving the stability of pramipexole or its salt preparation, and further provides a pramipexole hydrochloride oral liquid with excellent stability and oral absorption effect. The pramipexole hydrochloride oral liquid of the present invention is prepared through a simple process, and shows bioequivalence with the tablet containing pramipexole hydrochloride. The invention perfectly realizes multi-dose administration of pramipexole hydrochloride and improves the compliance and accessibility of medication for patients.
    Type: Grant
    Filed: January 8, 2021
    Date of Patent: October 31, 2023
    Assignees: CHANGZHOU NO.4 PHARMACEUTICAL FACTORY CO. LTD, BEIJING DO-PHARMA TECH CO. LTD
    Inventors: Xinhua Fan, Yanyuan Zhang, Yun He, Pengfei Li, Xiang Zhang, Longhao Wu, Peng Peng, Sujing Zhuang, Li Xiao, Yongrui Tu
  • Publication number: 20230322953
    Abstract: Disclosed is a binding protein having at least two protein functional regions, the binding protein comprising a protein functional region A and a protein functional region B; the protein functional region A and the protein functional region B target different antigens or epitopes, the protein functional region A is a Fab or a scFv structure, the protein functional region B is a VH structure, and there are one or more of each of the protein functional region A and the protein functional region B. A multi-specific binding protein has a smaller molecular weight, fewer polypeptide chains, and a simpler structure. By means of different structure types, relative positions, binding valence and other parameters, the functional activities for different targets can be adjusted, and then different combinations of activities can be designed so as to meet the needs of different dose combinations of clinical combinations.
    Type: Application
    Filed: June 29, 2021
    Publication date: October 12, 2023
    Applicant: HARBOUR BIOMED (SHANGHAI) CO., LTD
    Inventors: Yun HE, Lei SHI, Haishan LUO, Qiang LV, Jinqiu HE, Zenglin PEI, Yongqiang WANG, Chen ZHONG, Bing HUANG, Jianxun ZHAO, Xingxing JIA, Xuekun ZHANG, Chuchu ZHAO, Fei CHEN, Lei NIU
  • Publication number: 20230303698
    Abstract: The present invention provides a binding protein and use thereof, wherein the binding protein comprises a first protein functional region binding to a targeting moiety of an antigen on a target cell, and a second protein functional region binding to an effector moiety of an antigen on an immune effector cell; and the binding protein is selected from the following structure: the first protein functional region is of a Fab structure, the second protein functional region is of a VH structure or a Fab structure, and the first protein functional region and the second protein functional region are arranged sequentially from the N-terminus to the C-terminus of the binding protein. The binding protein can bring the immune effector cell and the specific target cell together, efficiently and selectively activate the immune effector cell in a microenvironment of the specific target cell, further enhance immune responses, and reduce toxic and side effects caused by non-specific activation of peripheral immune cells.
    Type: Application
    Filed: June 29, 2021
    Publication date: September 28, 2023
    Inventors: Yun HE, Lei SHI, Xiaodong WU, Chen ZHONG, Bing HUANG, Yiping RONG
  • Publication number: 20230287143
    Abstract: Provided is a binding protein, which comprises a protein functional region A and a protein functional region B, both of which target different antigens or different epitopes of antigens. The protein functional region A is Fab; the protein functional region B is VH; and the binding protein also comprises an Fc homodimer. There are two of both the protein functional region A and the protein functional region B. The binding protein has a left-right symmetrical structure. The binding protein consists of the protein functional region A, the protein functional region B and Fc in sequence from the N-terminus to the C-terminus, wherein the protein functional region A and the protein functional region B are connected by means of L1, and the protein functional region B is connected to the Fc by means of L2. The binding protein has a relatively small molecular mass, few polypeptide chains and a simpler structure. The protein has a versatile structure and may be applied to a variety of different target combinations.
    Type: Application
    Filed: June 29, 2021
    Publication date: September 14, 2023
    Inventors: Yun HE, Lei SHI, Bing HUANG, Chen ZHONG, Qiang LV, Ming WANG
  • Patent number: 11750809
    Abstract: An encoding method with multiple image block division manners is disclosed, including: determining a division manner and a division direction of an image block; dividing the image block to obtain image subblocks sequentially arranged horizontally or vertically; determining whether the image subblocks need subdivision, and if subdivision is not needed, predicting the encoding object in the frame according to the image subblocks, to obtain residual data; performing transformation, quantization, and entropy encoding for the residual data so as to obtain coded residual data; and writing the division manner of the image block, the division direction of the image block, an identifier indicating whether the image subblocks need subdivision, and the coded residual data into a bitstream. By applying the encoding method, better prediction accuracy can be achieved when the image block presents a small change of pixel value in the horizontal or vertical direction.
    Type: Grant
    Filed: February 16, 2022
    Date of Patent: September 5, 2023
    Assignees: Huawei Technologies Co., Ltd., Tsinghua University
    Inventors: Changcai Lai, Xiaoran Cao, Yongbing Lin, Lingzhi Liu, Yun He
  • Publication number: 20230262221
    Abstract: A method and device for coding and decoding are disclosed. The method includes: dividing a picture to be encoded into several slices, each containing macroblocks continuous in a designated scanning sequence in the picture; dividing slices in the picture into one or more slice sets according to attribute information of the slices, each slice set containing one or more slices; and encoding the slices in the slice sets according to slice and slice set division information to get a coded bit stream of the picture. The decoding method includes: obtaining slice and slice set division information from a bit stream to be decoded and decoding the bit stream according to the obtained slice and slice set division information. The invention improves the performance of video transmission effectively and realizes region based coding. The implementation of coding and decoding is simple and the complexity of coding and decoding systems is reduced.
    Type: Application
    Filed: April 18, 2023
    Publication date: August 17, 2023
    Applicants: HUAWEI TECHNOLOGIES CO., LTD., TSINGHUA UNIVERSITY
    Inventors: Xiaozhen Zheng, Zhen Mao, Ziyuan Wang, Yun He, Xiaozhong Xu, Jianhua Zheng
  • Publication number: 20230242658
    Abstract: The present invention discloses a 4-1BB-binding protein and use thereof. The 4-1BB-binding protein comprises a heavy chain variable region, wherein the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3, wherein the HCDR1 comprises a sequence as set forth in SEQ ID NO: 15 or a variant 1 thereof, or SEQ ID NO: 16; the HCDR2 comprises a sequence selected from SEQ ID NO: 60 or a variant 2 thereof, and SEQ ID NO: 50 or a variant 4 thereof; the HCDR3 comprises a sequence as set forth in SEQ ID NO: 103 or a variant 3 thereof, SEQ ID NO: 333 or a variant 5 thereof, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 116, SEQ ID NO: 326, SEQ ID NO: 331, SEQ ID NO: 334 or SEQ ID NO: 96. The 4-1BB-binding protein of the present invention is a fully human antibody having the binding activity to human 4-1BB and cynomolgus monkey 4-1BB. Some 4-1BB-binding proteins are only half the size of conventional IgG antibodies; they can be well used for bispecific antibodies.
    Type: Application
    Filed: June 29, 2021
    Publication date: August 3, 2023
    Applicant: NONA BIOSCIENCES (SUZHOU) CO., LTD.
    Inventors: Lei SHI, Bing HUANG, Yun HE, Xin GAN, Fei CHEN, Jianxun ZHAO, Bo XIANG
  • Publication number: 20230235011
    Abstract: A Fc-CD80 fusion protein has a CD80 extracellular domain (ECD) linked to a C-terminal of an immunoglobulin Fc domain. The Fc-CD80 fusion protein can be used for the preparation of a conjugate, the conjugate including the Fc-CD80 fusion protein as a first component, and a second component containing a second effector molecule, the second component being located at an N-terminal of the first component. In addition, a conjugate including the Fc-CD80 fusion protein, a pharmaceutical composition including the Fc-CD80 fusion protein and/or the conjugate are effective for the treatment or prevention of cancerous diseases in individuals.
    Type: Application
    Filed: May 25, 2021
    Publication date: July 27, 2023
    Inventors: Pinliang HU, Jing ZOU, Weidong HONG, Yun HE, Lingyun SONG, Wendi YANG
  • Publication number: 20230235090
    Abstract: Provided are a bispecific antibody and use thereof. The bispecific antibody comprises a B7-H4-targeting antigen-binding domain and a 4-1BB-targeting antigen-binding domain. The bispecific antibody has one or two or three sites for binding to 4-1BB, along with a novel fully human B7-H4 antibody. The bispecific antibody specifically binds to tumor cells by targeting B7-H4, reducing toxicity induced by 4-1BB activation. In addition, the bispecific antibody of the present invention comprises a human Fc fragment, and thus retains the binding of Fc to FcRn and has a longer half-life.
    Type: Application
    Filed: June 29, 2021
    Publication date: July 27, 2023
    Applicant: HARBOUR BIOMED US, INC.
    Inventors: Lei SHI, Chen ZHONG, Xiaodong WU, Yun HE, Fei CHEN, Xiaocheng LV, Jinli XIE, Yiping RONG, Bing HUANG, Fangfang DU, Jianxun ZHAO
  • Publication number: 20230193343
    Abstract: Apparatus and methods for determining the blood glucose concentration of a patient are disclosed A saliva glucose measurement strip is used in conjunction with a glucose measurement device to measure an electrochemical signal of a saliva sample and the measured electrochemical signal is correlated to a blood glucose convention.
    Type: Application
    Filed: December 20, 2022
    Publication date: June 22, 2023
    Inventors: PRIYANKA AGRAWAL, VLADIMIR BASHKIROV, STEPHEN F. DREYER, YUN HE, IGOR IVANOV, CHING JINN LIN, LANXIN SHEN, HUI TIAN
  • Patent number: 11667704
    Abstract: The invention relates to the field of medical biotechnology. Specifically, the present invention relates to a fusion protein containing an anti-interleukin-17 antibody and a tumor necrosis factor receptor extracellular region, a polynucleotide encoding the fusion protein, a vector comprising the polynucleotide, a host cell comprising the polynucleotide or the vector, and the use of the fusion protein for the treatment, prevention, and/or diagnosis of a related disease in an individual.
    Type: Grant
    Filed: November 6, 2018
    Date of Patent: June 6, 2023
    Assignees: BEIJING BEYOND BIOTECHNOLOGY CO., LTD, HANGZHOU POLYMED BIOPHARMACEUTICALS, INC.
    Inventors: Pinliang Hu, Jing Zou, Weidong Hong, Yun He, Jie Bai, Lingyun Song, Wendi Yang, Zhijian Lv, Shaoyun Xiang
  • Patent number: D986932
    Type: Grant
    Filed: November 26, 2021
    Date of Patent: May 23, 2023
    Assignee: SHENZHEN ATOMSTACK TECHNOLOGIES CO., LTD
    Inventors: Huigang Lin, Yun He, Zebin Li
  • Patent number: D992505
    Type: Grant
    Filed: November 26, 2021
    Date of Patent: July 18, 2023
    Assignee: SHENZHEN ATOMSTACK TECHNOLOGIES CO., LTD
    Inventors: Huigang Lin, Yun He, Zebin Li
  • Patent number: D992518
    Type: Grant
    Filed: November 26, 2021
    Date of Patent: July 18, 2023
    Assignee: SHENZHEN ATOMSTACK TECHNOLOGIES CO., LTD
    Inventors: Huigang Lin, Yun He, Zebin Li
  • Patent number: D1002684
    Type: Grant
    Filed: November 26, 2021
    Date of Patent: October 24, 2023
    Assignee: SHENZHEN ATOMSTACK TECHNOLOGIES CO., LTD
    Inventors: Huigang Lin, Yun He, Zebin Li
  • Patent number: D1003328
    Type: Grant
    Filed: November 26, 2021
    Date of Patent: October 31, 2023
    Assignee: SHENZHEN ATOMSTACK TECHNOLOGIES CO., LTD
    Inventors: Huigang Lin, Yun He, Zebin Li